The combination with a PD-1/Mg MNs further inhibits tumor immune escape mechanisms, enhancing CD8+ T cell infiltration into the tumor microenvironment and achieving systemic immunity capable of suppressing distant tumor growth solely through localized microneedle administration. Here, CD8A is linked to neoplasm.